Fig 1: Immunohistochemical control images. Normal tonsil tissue was used as a control showing both (A) positively stained lymphoid tissue and the (B) absence of staining for squamous mucosa. (C) Normal tonsil tissue showing strong MYC expression having >10% MYC positive lymphoid areas, with a weak, distinct staining of the mantle zone B-cells (~10%). (D) Normal tonsil tissue with MUM1 staining. (E) Normal renal proximal tubule epithelial cells stained with CD10 showing a strong, predominantly membranous and cytoplasmic staining; distal tubules showing absence of staining. MUM1, multiple myeloma 1. Magnifications: Panel A, C, D, ×400; panel B, ×200.
Fig 2: FIGUREAAV-miR-29a could inhibit valvular EndMT in rats with CKD. The changes in EndMT markers in different models. (A) The pattern diagram of the research design. (B) The level of miR-29a-5p in the CTL, CKD and CKD+AAV-29a-5p groups. (C) mRNA levels of endothelial marker (CD31) and mesenchymal markers (a-SMA, FSP1, CD44, CD10) in different models. (D, E) Protein levels of endothelial marker and mesenchymal markers in different models. (F, G) Fluorescence staining of CD31with FSP1 in aortic valves. Data were presented as the mean ± SD. n = 4 per group. **P < .01 vs CTL group. ***P < .001 vs CTL group. #P < .01 vs CKD group. ## P < .01 vs CKD group. ###P < .001 vs CKD group
Fig 3: Histopathological images of the mediastinal biopsy specimen. (A) Large numbers of lymphocytes, medium to large, with oval or round nuclei containing fine chromatin and scanty cytoplasm (hematoxyclin and eosin staining, ×20 magnification). Immunohistochemical staining (compared with appropriate controls) revealed strong, positive expression for (B) CD20 (membranous, diffuse), (C) BSAP (nuclear, partial), (D) CD10 (membranous, diffuse), (E) BCL6 (nuclear), and (F) BCL2 (membranous). Tissue sections showed low expression for (G) multiple myeloma 1 (no nuclear staining) and (H) MYC. (I) High expression of proliferative marker Ki-67 (80%).
Fig 4: PTH-induced EndMT in VC of CKD rats. The changes in EndMT markers in the different models. (A) mRNA levels of endothelial marker (CD31) and mesenchymal markers (a-SMA, FSP1, CD44, CD10) in the different models. (B, C) Protein levels of endothelial marker and mesenchymal markers in different models. (D-E) Fluorescence staining of CD31with FSP1 in aortic valves. Data were presented as the mean ± SD. n = 4 per group. **P < .01 vs CTL group. ***P < .001 vs CTL group. # P < .01 vs CKD group. ## P < .01 vs CKD group
Fig 5: IHC images of the indicators for differential diagnosis of primary renal MALT lymphoma and other blood system tumors. Representative IHC images for CD21 and CD23 showed an irregular and damaged follicular dendritic network which was related to lymphoma. A negative representative for markers of germinal center lymphocyte, BCL-6 and CD10 may help differentiate from follicular lymphoma. Moreover, a negative representative of CyclinD1 may distinguish between mantle cell lymphoma or partial plasmablastic lymphoma and primary renal MALT lymphoma.
Supplier Page from Abcam for Anti-CD10 antibody [EPR22867-118]